Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1)
-
Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1)
structure -
-
CAS No:
253863-00-2
-
Formula:
C22H20ClN5O.ClH
-
Chemical Name:
Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1)
-
Synonyms:
Benzonitrile,4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-,hydrochloride (1:1);Benzonitrile,4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-,monohydrochloride;L 778123
-
CAS No:
Description
L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.IC50 value: 2 nM [1]Target: FPTasein vitro: L-778123 can completely inhibit Ki-Ras prenylation. [1] L-778123 as a farnesyltransferase inhibitor can have a good cytotoxic activity as a classic anti-cancer agent. [2]in vivo: In the dog model, L-778123 inhibits HDJ2 prenylation and produces measurable, albeit slight (5%), levels of unprenylatedRap1A in PBMCs. [1]
L-778,123 hydrochloride is the hydrochloride salt of L-778,123. It is a dual inhibitor of FPTase and GGPTase-I (IC50 of 2nM and 98nm, respectively) and exhibits anti-cancer properties. It has a role as an antineoplastic agent, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor, an EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor and a radiosensitizing agent. It contains a L-778,123 (free base).|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123 is a benzonitrile derivative capable of inhibiting some prenyltransferases. L-778,123 is a dual inhibitor of farnesyl:protein and geranylgeranyl:protein transferases; both enzymes catalyze prenylation of oncoprotein KRAS, a prerequisite step in activation of KRAS in signal transduction pathway of apoptosis. Although this agent was developed in part as an anti-KRAS agent, L-778,123 failed in a Phase I trial to inhibit KRAS, which is associated with many types of solid tumors.
Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1) Basic Attributes
442.341
441.112305
2A2059P49U
DTXSID60180034
C1840
Computed Properties
Molecular Weight:442.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:5
Exact Mass:441.1123157
Monoisotopic Mass:441.1123157
Topological Polar Surface Area:65.2
Heavy Atom Count:30
Complexity:614
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes
Learn More Other Chemicals
-
Benzonitrile, 3-[(1S,2S)-2-amino-1-[(4-chlorophenyl)methyl]propyl]-, hydrochloride (1:1)
610791-48-5
-
Benzonitrile, 2-amino-5-methoxy-, hydrochloride (1:1)
115661-38-6
-
Benzonitrile, 3-(2-aminoacetyl)-, hydrochloride (1:1)
50916-56-8
-
Benzonitrile, 4-[(3-amino-1-piperidinyl)methyl]-, hydrochloride (1:1) Formula
1353972-48-1
-
Benzonitrile, 3-(aminomethyl)-, hydrochloride (1:1) Formula
40896-74-0
-
Benzonitrile, 4-amino-2,5-dimethoxy-, hydrochloride (1:1) Formula
6368-91-8
-
Benzonitrile, 3-(1-aminoethyl)-, hydrochloride (1:1) Structure
1188264-05-2
-
Benzonitrile, 4-hydrazinyl-, hydrochloride (1:1) Structure
2863-98-1
Benzonitrile, 4-[[5-[[4-(3-chlorophenyl)-3-oxo-1-piperazinyl]methyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:1)
SDSRequest for Quotation